[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 74 of about 74
1. Lazaraki G, Tragiannidis D, Xirou P, Nakos A, Pilpilidis I, Katsos I: Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report. Cases J; 2009;2:6462

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report.
  • Lipomas of the colon are benign tumors that rarely occur.
  • They are usually asymptomatic but occasionally they present with clinical manifestations depending on tumor size, localization and complications, which often lead to diagnostic difficulty.
  • During colonoscopy a giant polyp of over 50 mm in its bigger diameter, with a thick stalk of 2 cm, located in the transverse colon, was revealed.
  • In this report discussion over endoscopic resection of colonic lipomas mimicking neoplasms is also performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Nov;30(11):888-93 [3677966.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2826-7 [18270829.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):441-4 [4645612.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jul;5(3):713-21 [8829328.001]
  • [Cites] Surg Endosc. 1998 Jan;12(1):42-5 [9419301.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2143-4 [10950091.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1295-7 [11316189.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1944-6 [11419863.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):929-31 [12024158.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):756-9 [15855988.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):988-90 [16301055.001]
  • [Cites] Indian J Gastroenterol. 2007 Sep-Oct;26(5):254-5 [18227586.001]
  • [Cites] Eur J Surg. 1991 Jan;157(1):51-5 [1675882.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):532-3 [2152245.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):435-8 [2227312.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Am Surg. 1985 Aug;51(8):449-54 [4026070.001]
  • (PMID = 20181161.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827102
  •  go-up   go-down


2. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


3. Jung SH, Paik CN, Jung JH, Lee KM, Chung WC, Yang JM: Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis. Gut Liver; 2009 Sep;3(3):215-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.
  • Mesenteric fibromatosis (MF) is a rare benign mesenchymal lesion that can occur throughout the gastrointestinal tract, especially small bowel.
  • Its biological behavior is intermediate between benign fibrous tissue proliferation and malignant fibrosarcoma.
  • In previously reported cases of MF, we could find colonic obstruction or ureter obstruction, but simultaneous involvement of colon and ureter was not able to be seen.
  • We described a patient that presented with colonic obstruction and hydroureteronephrosis due to MF at sigmoid colon which mimicked submucosal tumor such as gastrointestinal tumor.
  • This case resulted in a positive positron emission tomography scan suggesting malignant neoplasm, but beta-catenin positivity on immunohistochemical staining separated MF from gastrointestinal stromal tumor and sclerosing mesenteritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5985-8 [18023087.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):924-6 [17205200.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5226-8 [16127758.001]
  • [Cites] Histopathology. 1994 Nov;25(5):469-73 [7532614.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):275-9 [1853806.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):335-41 [2321698.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):93-8 [14750246.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] AJR Am J Roentgenol. 1991 Mar;156(3):539-42 [1899752.001]
  • (PMID = 20431749.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852704
  • [Keywords] NOTNLM ; Colonic obstruction / Hydroureteronephrosis / Mesenteric fibromatosis
  •  go-up   go-down


Advertisement
4. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


5. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • The patient underwent genetic testing for Cowden syndrome (PTEN gene), Carney complex (PRKAR1A gene), and multiple endocrine neoplasia syndrome type 1 (MEN1 gene); no deleterious mutations were identified.
  • DISCUSSION: The constellation of benign and malignant neoplasms in the context of this patient's familial testicular cancer raised the possibility that these might be manifestations of a known hereditary susceptibility cancer syndrome; however, genetic testing for the three syndromes that were most likely to explain these findings did not show any mutation.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


7. Consolo P, Luigiano C, Pellicano R, Ferrara F, Giacobbe G, Morace C, Pallio S, Tortora A, Melita G, Bassi M, D'Imperio N, Alibrandi A, Familiari L: Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size. Minerva Med; 2010 Oct;101(5):311-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size.
  • The most frequent type of neoplasm was villous adenoma (76.1%).
  • CONCLUSION: ER is a safe and effective procedure for removing benign appearing very large colorectal neoplasms.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Hemostasis, Surgical / methods. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / therapy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Minerva Med. 2011 Apr;102(2):XV. Giuseppinella, M [corrected to Melita, G]
  • (PMID = 21048553.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • We have used quantitative real-time PCR to investigate the expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon tissue samples.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


9. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • Based on the frequency of colonic polyps, screening colonoscopy should be considered in all patients with IPMN.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


10. Törnroos A, Garvin S, Olsson H: The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. Acta Oncol; 2009;48(8):1152-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.
  • BACKGROUND. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients.
  • This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen.
  • We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linköping University Hospital, Linköping, Sweden between the years 2000 and 2008.
  • Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863223.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • Increased maspin expression was also found in three MSI-H colon cancer cell lines, but not in three MSS colon cancer cell lines by RT-PCR and western blot analyses.
  • Intense nuclear maspin immunostaining was seen specifically in MSI-H tumours (p = 0.013), de-differentiated tumours (p = 0.006), and at the invasion front.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


12. Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D: Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer; 2010 Jul;9(3):179-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature.
  • Angiolymphoid hyperplasia with eosinophilia (AHE) of the colon is a rare entity.
  • Here, we report a third case that presented as a transverse colonic mass mimicking cancer both clinically and radiologically.
  • Whether AHE is a reactive process or a neoplastic process (either a benign vascular neoplasm or a T-cell lymphoproliferative disorder) is still under debate.
  • However, it is important to recognize this entity as a cause of colonic mass to avoid a misdiagnosis of malignancy.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colonic Diseases / pathology. Colonic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20643624.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


13. Majewska U, Banaś D, Braziewicz J, Góźdź S, Kubala-Kukuś A, Kucharzewski M: Trace element concentration distributions in breast, lung and colon tissues. Phys Med Biol; 2007 Jul 7;52(13):3895-911
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trace element concentration distributions in breast, lung and colon tissues.
  • The concentrations of Fe, Cu, Zn and Se in cancerous and benign tissues of breast, lung and intestine (colon) have been determined.
  • Finally, the log-rank test has been applied to compare the elemental concentration distributions between cancerous and benign tissues of the same organ, between cancerous tissues and between benign tissues taken from different organs.
  • Comparing benign and malignant neoplastic tissues, statistically significant differences have been found between Fe and Se concentration distributions of breast as well as for Cu and Zn in the case of lung tissues and in the case of colon tissues for Zn.
  • The concentrations of all elements have been found to be statistically different in cancer tissues as well as in benign ones when comparing the different organs, i.e. groups 'breast-colon' and 'breast-lung'.
  • Concentrations of Fe and Cu have been found to be statistically different in lung and colon cancerous tissues.
  • For benign tissues of lung and colon a statistically significant difference has been found only for Zn.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Lung / metabolism. Lung Neoplasms / metabolism. Spectrometry, X-Ray Emission / methods. Trace Elements / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Iron / chemistry. Male. Middle Aged. Neoplasm Metastasis. Selenium / chemistry. Zinc / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664584.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Trace Elements; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc
  •  go-up   go-down


14. Seo GJ, Sohn DK, Han KS, Hong CW, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH: Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps. World J Gastroenterol; 2010 Jun 14;16(22):2806-11
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 50 polyps identified, 34 (68%) were benign and 16 (32%) were malignant.
  • The recurrence rate after EPMR was 3.1% for benign polyps and 33.3% for malignant polyps (P < 0.05).
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):697-700 [10840302.001]
  • [Cites] J Gastroenterol Hepatol. 2010 Jan;25(1):84-9 [19793173.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):212-8 [12584639.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Gut. 2004 Apr;53(4):568-72 [15016753.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Am J Gastroenterol. 1977 May;67(5):430-8 [900105.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):128-32 [2032596.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):303-9 [1607080.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):840-4 [17253129.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):229-51, ix [18313548.001]
  • [Cites] World J Gastroenterol. 2008 Apr 21;14(15):2364-9 [18416463.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4289-95 [18666315.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):615 [18760188.001]
  • [Cites] J Gastroenterol. 2008;43(9):641-51 [18807125.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):343-52 [19517168.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • (PMID = 20533602.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2883138
  •  go-up   go-down


15. Chung WC, Kim HK, Yoo JY, Lee JR, Lee KM, Paik CN, Jang UI, Yang JM: Colonic lymphangiomatosis associated with anemia. World J Gastroenterol; 2008 Oct 7;14(37):5760-2
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic lymphangiomatosis associated with anemia.
  • Multiple colonic lymphangioma named as lymphangiomatosis is considered an extremely rare disease.
  • Although lymphangioma is a benign tumor and most colonic lymphangiomas do not cause symptoms and do not require treatment, resection of lymphangioma is necessary in the presence of symptoms such as abdominal pain, bleeding, intussusceptions.
  • We report a case of colonic lymphangiomatosis in a man who presented with abdominal discomfort and anemia, which was diagnosed and treated with endoscopic snare polypectomy.
  • [MeSH-major] Anemia / etiology. Colonic Neoplasms / complications. Lymphangioma / complications

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(2):146-8 [10936792.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):781-4 [11115919.001]
  • [Cites] J Nippon Med Sch. 2001 Jun;68(3):262-5 [11404774.001]
  • [Cites] J Gastroenterol. 2002;37(5):381-6 [12051538.001]
  • [Cites] Surg Today. 2002;32(8):734-7 [12181728.001]
  • [Cites] J Gastroenterol. 2003;38(2):181-5 [12640534.001]
  • [Cites] Am J Dig Dis. 1975 Nov;20(11):1076-80 [1200000.001]
  • [Cites] Arch Surg. 1985 Nov;120(11):1266-9 [4051731.001]
  • [Cites] Radiology. 1994 Sep;192(3):697-702 [8058936.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):252-4 [7789688.001]
  • [Cites] Gastrointest Endosc. 1997 Feb;45(2):204-6 [9041015.001]
  • [Cites] J Clin Gastroenterol. 1997 Apr;24(3):186-7 [9179742.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):383-6 [9412929.001]
  • [Cites] J Gastroenterol. 1999 Aug;34(4):520-4 [10452688.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1747-53 [16133983.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Oct;16(5):530-3 [17004884.001]
  • (PMID = 18837097.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2748215
  •  go-up   go-down


16. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M: Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun; 2005 Jul 8;332(3):800-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer.
  • Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells.
  • COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry.
  • Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition.
  • Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / biosynthesis. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Membrane Proteins. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907789.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 69533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


17. Goldstein NS: Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol; 2006 Jan;125(1):132-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases.
  • Eight sessile serrated adenoma (SSA), right colon polypectomies with focal invasive adenocarcinoma or high-grade dysplasia were studied to identify features indicating a high risk of transformation and characterize the morphologic features of serrated dysplasia; 6 cases had invasive adenocarcinoma; 2 were high-grade dysplasia.
  • All 8 cases had an abrupt transition from benign to high-grade in situ or invasive malignancy.
  • In the 6 invasive adenocarcinomas, the neoplasm extended directly down into the submucosa without lateral intramucosal spread.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Chromosomal Instability. Colonic Neoplasms / pathology. Microsatellite Repeats
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Aged, 80 and over. Carrier Proteins / analysis. Cell Transformation, Neoplastic / pathology. Colonic Polyps / pathology. Epithelium / pathology. Humans. Middle Aged. Nuclear Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483002.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


18. Loungnarath R, Mutch MG, Birnbaum EH, Read TE, Fleshman JW: Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon. Dis Colon Rectum; 2010 Jul;53(7):1017-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy using cancer principles is appropriate for colonoscopically unresectable adenomas of the colon.
  • PURPOSE: This study was undertaken to determine the risks of cancer in unresectable polyps and to compare the short-term outcome of laparoscopic colectomy with that of open colectomy for benign polyps.
  • Oncologic resection of the colon should be performed for all colonoscopically unresectable polyps due to the risk of cancer.
  • [MeSH-major] Adenoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Colonoscopy / contraindications. Laparoscopy / methods
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Oldenburg A, Albrecht T: [Baseline and contrast-enhanced ultrasound of the liver in tumor patients]. Ultraschall Med; 2008 Oct;29(5):488-98
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
  • Conventional sonography is the most commonly used modality for liver imaging in tumor patients.
  • The majority of liver metastases are hypoechoic and well defined in baseline ultrasound (US), while detection of isoechoic or small liver metastases <1 cm is difficult and the differentiation of liver metastases from benign liver lesions and other malignant liver tumors can be impossible with baseline US.
  • Furthermore, the typical enhancement patterns of the different benign and malignant liver lesions allow reliable characterization and differentiation from liver metastases in the majority of cases.
  • This paper provides information about the advantages and expedient application of contrast-enhanced ultrasound (CEUS) in tumor patients.
  • [MeSH-major] Contrast Media. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Colonic Neoplasms / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neovascularization, Pathologic / ultrasonography. Reproducibility of Results. Sarcoma, Ewing / pathology. Sarcoma, Ewing / ultrasonography. Ultrasonography, Doppler / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ultraschall Med. 2009 Apr;30(2):125-7 [19340726.001]
  • (PMID = 19241505.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


20. Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S: Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol; 2006 Feb;80(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional alterations that occur in UC-associated neoplasia in the progression from normal mucosa through dysplastic epithelium to invasive cancer have not been described.
  • We used Affymetrix U95Av2 microarrays to assess differential gene expression in the neoplastic progression of UC tissue from the colonic mucosa of individuals with benign UC, UC-dysplasia-associated lesions or masses, and UC adenocarcinoma.
  • There were, however, important differences that suggest that different molecular events may occur in the development of UC-associated neoplasia.
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277983.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


21. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate markers in colon carcinoma.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • Glycoconjugate markers for colon cancer include aberrant: mucins covering the surface of the colon epithelial cells, cadherins, selectins and Ig-like adhesion molecules mediating cell-cell adhesion, integrins and integral membrane proteoglycans responsible for adhesion of colon epithelial cells to extracellular matrix, glycoconjugate components of ECM, as well as lysosomal membrane glycoproteins and exoglycosidases.
  • Detection of colon cancer at early non malignant stage is crucial in its prevention and eradication.
  • As colon cancer is the effect of accumulation many somatic mutations in oncogens, supressors, mismatch repair genes and many genes responsible for posttranslational modifications of proteins, multidirectional approach should be applied for its detection.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


22. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • This case report shows that the use of genetic markers in stool testing has the potential to detect colon cancer in its very early stages when treatment is simple and often successful.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


23. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


24. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


25. Benedix F, Köckerling F, Lippert H, Scheidbach H: Laparoscopic resection for endoscopically unresectable colorectal polyps: analysis of 525 patients. Surg Endosc; 2008 Dec;22(12):2576-82
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the high rate of malignant transformation despite initially benign histology continues to be a problem.
  • METHODS: Within the framework of a prospective multicenter observational study, all patients with adenomatous polyps unsuitable for endoscopic removal and with benign histology were investigated.
  • In the elderly patient presenting with comorbidities limited resection aiming to minimize surgical trauma in potentially benign disease may be considered.
  • [MeSH-major] Adenocarcinoma / surgery. Adenomatous Polyps / surgery. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colectomy / methods. Colonoscopy. Disease Progression. Disease-Free Survival. Female. Humans. Laparotomy / statistics & numerical data. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications / epidemiology. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626704.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


26. Zarkovic K, Uchida K, Kolenc D, Hlupic L, Zarkovic N: Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis. Free Radic Res; 2006 Jun;40(6):543-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis.
  • It suppresses p53 synthesis acting as potent carcinogenic factor for oral, respiratory and bladder carcinomas, while its possible association with colon carcinogenesis was not studied so far.
  • We used genuine monoclonal antibody to evaluate immunohistochemical distribution of acrolein-protein adducts in 113 human colon tumours.
  • The presence of acrolein-protein adducts was increasing with respect to colon carcinogenesis, from moderate appearance in tubular and villotubular low-grade adenomas to abundant and diffuse distribution in high-grade villotubular adenomas and Dukes A carcinomas.
  • However, in advanced Dukes B and C carcinomas acrolein was hardly noticed, although, its protein adducts were found abundant in non-malignant colon epithelium of these patients.
  • According to these findings, acrolein seems to be lipid peroxidation product associated with transition from benign into malignant colon tumours.
  • [MeSH-major] Acrolein / metabolism. Colonic Neoplasms / metabolism. Lipid Peroxidation
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Tissue Distribution

  • Hazardous Substances Data Bank. ACROLEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753831.001).
  • [ISSN] 1071-5762
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7864XYD3JJ / Acrolein
  •  go-up   go-down


27. Metaxas G, Tangalos A, Pappa P, Papageorgiou I: Mucinous cystic neoplasms of the mesentery: a case report and review of the literature. World J Surg Oncol; 2009;7:47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been rare reports involving the mesentery as a primary tumour site.
  • At laparotomy, the mass was fixed within the colonic mesentery.
  • Histology demonstrated a benign mucinous cystadenoma.
  • METHODS AND RESULTS: We review the literature on mucinous cystic neoplasms of the mesentery and report on the pathogenesis, biologic behavior, diagnosis and treatment of similar extra-ovarian tumors.
  • We propose an updated classification of mesenteric cysts and cystic tumors.
  • CONCLUSION: Mucinous cystic neoplasms of the mesentery present almost exclusively in women and must be considered in the differential diagnosis of mesenteric tumors.
  • Only full histological examination of a mucinous cystic neoplasm can exclude a borderline or malignant component.
  • An updated classification of mesenteric cysts and cystic tumors is proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol Surv. 1972 Mar;27(3):133-46 [4614139.001]
  • [Cites] Am J Surg. 1975 Jun;129(6):709-11 [1130615.001]
  • [Cites] Obstet Gynecol. 1977 Apr;49(4):486-8 [854250.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Conn Med. 1980 Mar;44(3):140-1 [7363617.001]
  • [Cites] Arch Surg. 1984 Jul;119(7):838-42 [6732494.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):109-12 [3942415.001]
  • [Cites] Gynecol Oncol. 1986 May;24(1):103-12 [3699572.001]
  • [Cites] Arch Pathol Lab Med. 1987 Mar;111(3):282-4 [3827533.001]
  • [Cites] Radiology. 1987 Aug;164(2):327-32 [3299483.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 2):1030-2 [3374916.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):903-8 [1415909.001]
  • [Cites] Radiographics. 1992 Nov;12(6):1051-68 [1439011.001]
  • [Cites] South Med J. 1993 Feb;86(2):173-6 [8434287.001]
  • [Cites] Pancreas. 1993 Sep;8(5):647-9 [8302802.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jan;13(1):73-9 [8112958.001]
  • [Cites] Surg Laparosc Endosc. 1994 Feb;4(1):59-61 [8167868.001]
  • [Cites] Radiographics. 1994 Jul;14(4):729-37 [7938764.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2085-7 [7942747.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Aust N Z J Surg. 1994 Nov;64(11):741-4 [7945079.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):88-90 [9066755.001]
  • [Cites] Eur J Surg. 1997 Sep;163(9):673-7 [9311474.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):698-703 [9630176.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Dig Dis Sci. 1999 Apr;44(4):768-74 [10219836.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Surg Endosc. 1999 Sep;13(9):937-9 [10449859.001]
  • [Cites] Br Med J. 1953 Jun 13;1(4823):1316 [13042235.001]
  • [Cites] Ginekol Pol. 2004 Jul;75(7):545-7 [15517775.001]
  • [Cites] Surg Clin North Am. 1950 Aug;30(4):1081-96 [15442870.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Eur J Surg. 2000 Mar;166(3):262-4 [10755343.001]
  • [Cites] Surgery. 2000 Jun;127(6):707-8 [10840368.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):429-31 [10924644.001]
  • [Cites] Dig Surg. 2000;17(4):323-8 [11053936.001]
  • [Cites] Eur J Pediatr Surg. 2000 Dec;10(6):402-3 [11215785.001]
  • [Cites] Surg Endosc. 2000 Jun;14(6):595 [11265068.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):74-9 [15665687.001]
  • [Cites] J Am Coll Surg. 2005 May;200(5):727-33 [15848365.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):927-31 [16112012.001]
  • [Cites] Surg Infect (Larchmt). 2005;6(2):259-61 [16128633.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):71-7 [16445818.001]
  • [Cites] Ann Trop Med Parasitol. 2006 Mar;100(2):137-42 [16492361.001]
  • [Cites] Hepatogastroenterology. 2006 Mar-Apr;53(68):286-90 [16608041.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):629-32 [16614979.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):655-7 [16731606.001]
  • [Cites] Dig Surg. 2006;23(3):186-91 [16837797.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):697-702 [17055859.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1715-7 [17076537.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Ulus Travma Acil Cerrahi Derg. 2007 Jan;13(1):74-7 [17310417.001]
  • [Cites] World J Surg. 2007 Mar;31(3):542-8 [17318706.001]
  • [Cites] Indian J Gastroenterol. 2007 May-Jun;26(3):137-8 [17704584.001]
  • [Cites] JOP. 2007;8(5):553-63 [17873459.001]
  • [Cites] Can J Surg. 2007 Oct;50(5):E3-4 [18031625.001]
  • [Cites] Eur J Pediatr Surg. 2007 Dec;17(6):400-3 [18072024.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):196-201 [17524597.001]
  • [Cites] Pediatr Dev Pathol. 2008 Jan-Feb;11(1):46-9 [18237233.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2280-3 [18407611.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):645-55 [18344868.001]
  • [Cites] Acta Chir Belg. 2008 May-Jun;108(3):354-5 [18710115.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4C):2309-15 [18751411.001]
  • [Cites] Pathol Int. 2008 Sep;58(9):601-5 [18801076.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5769-72 [18837099.001]
  • [Cites] Am J Clin Oncol. 2008 Oct;31(5):519-20 [18838891.001]
  • [Cites] Dig Liver Dis. 2008 Nov;40(11):837-46 [18499541.001]
  • [Cites] Emerg Radiol. 2009 Jul;16(4):327-30 [18604575.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Oct;98(10):1179-84 [11680992.001]
  • [Cites] Acta Cytol. 2001 Nov-Dec;45(6):941-7 [11726122.001]
  • [Cites] Surg Today. 2001;31(10):920-2 [11759891.001]
  • [Cites] World J Surg. 2002 Apr;26(4):462-9 [11910481.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):219 [11961656.001]
  • [Cites] Pancreatology. 2002;2(4):413-20 [12138231.001]
  • [Cites] Langenbecks Arch Surg. 2002 Nov;387(7-8):281-5 [12447553.001]
  • [Cites] Pathol Int. 2002 Oct;52(10):648-52 [12445137.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):45-57 [12533639.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):457-73; quiz 535-6 [12640160.001]
  • [Cites] J Gastroenterol. 2003;38(3):278-82 [12673452.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):515-25 [12684617.001]
  • [Cites] Acta Med Austriaca. 2003;30(2):61-4 [12752092.001]
  • [Cites] Acta Chir Belg. 2003 Jun;103(3):329-31 [12914373.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1221-8 [12960806.001]
  • [Cites] Ann Clin Lab Sci. 2003 Fall;33(4):465-70 [14584762.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1738-40 [14602331.001]
  • [Cites] Scand J Gastroenterol. 2003 Nov;38(11):1193-5 [14686726.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):2036 [14973761.001]
  • [Cites] J Reprod Med. 2004 Jan;49(1):65-7 [14976800.001]
  • [Cites] Ann Diagn Pathol. 2004 Apr;8(2):96-101 [15060888.001]
  • [Cites] Pathol Int. 2004 May;54(5):355-9 [15086841.001]
  • [Cites] J Urol. 2004 Jul;172(1):146-7 [15201756.001]
  • [Cites] Minerva Chir. 2004 Aug;59(4):405-11 [15278036.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1353-65 [15371613.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1412-4 [15484358.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):781-6 [15482568.001]
  • [Cites] Ann Surg. 1973 Jul;178(1):13-9 [4717705.001]
  • (PMID = 19454018.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2691402
  •  go-up   go-down


28. Vidal-González P, Cervantes-Castro J, Rojas-Reyna GA, Ramírez-Cerda C, Kunz-Martinez W, Toiber-Levy M: [Sclerosing mesenteritis. Presentation of three cases and review of the literature]. Cir Cir; 2008 Jul-Aug;76(4):343-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mesenteritis esclerosante. Presentación de tres casos y revisión de la literatura.
  • Sclerosing mesenteritis or panniculitis is a rare condition characterized by inflammation of the mesentery ranging from an acute to a chronic fibrotic process that can resemble an intestinal malignant neoplasm even though it is benign.
  • Its natural history is benign and in most cases is self-limited.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Cholecystectomy. Cholecystitis / etiology. Cholecystitis / surgery. Colchicine / therapeutic use. Colectomy. Combined Modality Therapy. Diverticulosis, Colonic / surgery. Duodenal Diseases / etiology. Duodenal Diseases / surgery. Gastric Bypass / adverse effects. Gastritis / etiology. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Laparotomy. Male. Methylprednisolone / therapeutic use. Middle Aged. Prognosis. Reoperation. Tissue Adhesions / complications. Tissue Adhesions / surgery

  • Genetic Alliance. consumer health - Sclerosing mesenteritis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778547.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; SML2Y3J35T / Colchicine; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 22
  •  go-up   go-down


29. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, Sedlackova E, Lipska L, Stahalova V: The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging; 2006 Jul;33(7):779-84
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Integrated FDG-PET/CT seems to offer promise for the differential diagnosis of benign and malignant lesions.
  • The aim of this study was to compare the value of FDG-PET and PET/CT in the detection of CRCR subsequent to colonic resection or rectal amputation.
  • The sensitivity, specificity and accuracy of PET and PET/CT were calculated for (a) intra-abdominal extrahepatic recurrences, (b) extra-abdominal and/or hepatic recurrences and (c) all recurrences, and tumour marker levels were analysed.
  • Two of these cases were due to increased accumulation in inflammatory foci in the bowel wall, while one was due to haemorrhaging into the adrenal gland.
  • CONCLUSION: FDG-PET/CT appears to be a very promising method for distinguishing a viable tumour from fibrous changes, thereby avoiding unnecessary laparotomy.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565845.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Grady WM: Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans; 2005 Aug;33(Pt 4):684-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic events in the colorectum and in colon cancer.
  • Colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and are believed to drive the histological progression of colon cancer.
  • Recently, epigenetic alterations, which include CGI (CpG island) DNA methylation, have been shown to occur in colon polyps and colon cancer.
  • The aberrant methylation of genes appears to co-operate with the genetic alterations to drive the initiation and progression of colon polyps to colon cancer.
  • These hypermethylated genes are not only probable pathogenic events affecting colon-cancer formation, but also neoplasm-specific molecular events that may be useful as molecular markers for colon tumours.
  • Furthermore, aberrant DNA methylation of tumour-suppressor genes may occur secondary to a genetic predisposition or to a field-cancerization effect in the colon and may be useful as molecular markers for the risk of developing colon cancer.
  • [MeSH-major] Colon / physiology. Colonic Neoplasms / genetics. Epigenesis, Genetic / genetics. Rectum / physiology
  • [MeSH-minor] Colonic Polyps / genetics. Gene Silencing. Genetic Markers. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042574.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 33
  •  go-up   go-down


31. Sidani SM, Tawil AN, Sidani MS: Extraction of a large self-amputated colonic lipoma: A case report. Int J Surg; 2008 Oct;6(5):409-11
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of a large self-amputated colonic lipoma: A case report.
  • Despite being the most common benign tumor of nonepithelial origin in the colon, colonic lipomas are nonetheless considered a rare occurrence.
  • The minority of patients presenting with symptomatic colonic lipoma are generally treated with resection.
  • We report a case of a symptomatic patient who, on presentation, was found to have a partially obstructing, self-amputated colonic mass on colonoscopy, requiring endoscopic fragmentation to extrude what was later histologically diagnosed to be a lipoma.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopes. Colonoscopy / methods. Lipoma / pathology. Lipoma / surgery
  • [MeSH-minor] Barium Sulfate. Colectomy / methods. Enema / methods. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947813.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


32. Tobalina Aguirrezábal E, Múgica Alcorta I, Portugal Porras V, Sarabia García S: [Implantation of laparoscopic colon surgery in a general surgery department]. Cir Esp; 2007 Mar;81(3):134-8
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Implantation of laparoscopic colon surgery in a general surgery department].
  • [Transliterated title] Implantación de la cirugía laparoscópica de colon en un servicio de cirugía general.
  • OBJECTIVE: To evaluate the viability, safety and short-term results of laparoscopic colon surgery during the first few years after its introduction in our department.
  • METHOD: Between January 2002 and December 2005, laparoscopic surgery was performed in patients with surgical indication for benign colon disease.
  • Surgery was indicated for benign disease in 60 patients (66%).
  • Distribution was left colon in 79 patients and right colon in 11 patients.
  • CONCLUSIONS: Laparoscopic surgery of the colon is safe and reproducible.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colonic Neoplasms / surgery. Colonoscopy / methods. Colonoscopy / statistics & numerical data. Surgery Department, Hospital / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Spain / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349237.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


33. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512601.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 192
  •  go-up   go-down


34. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • The established murine colon epithelial cell line provides a useful experimental model to further elaborate genetic and epigenetic factors that may promote or inhibit colon tumorigenesis and metastasis.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


35. Costa G, Tomassini F, Tierno SM, Venturini L, Frezza B, Cancrini G, Mero A, Lepre L: [Emergency colonic surgery: analysis of risk factors predicting morbidity and mortality]. Chir Ital; 2009 Sep-Dec;61(5-6):565-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Emergency colonic surgery: analysis of risk factors predicting morbidity and mortality].
  • [Transliterated title] Chirurgia del colon in urgenza: analisi dei fattori di rischio di morbilità e mortalità.
  • The aim of the present study was to identify risk factors for morbidity and mortality in patients submitted to emergency colonic surgery.
  • Between 1997 and 2008 157 patients, 106 of whom affected by colon cancer (67.5%) and 51 by benign disease (32.5%), were treated.
  • Among patients affected by cancer the mortality rate was 15% (16 patients) and the morbidity rate 23.6% (25 patients), while among the patients with benign disease the mortality rate was 7.8% (4 patients) and the morbidity rate 9.8% (5 patients).
  • Emergency surgery for both neoplastic and benign colonic disease is still associated with an increased risk of death.
  • [MeSH-major] Colectomy / adverse effects. Colectomy / methods. Colonic Diseases / mortality. Colonic Diseases / surgery. Emergency Treatment
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380259.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Jiang B, Ren T, Dong B, Qu L, Jin G, Li J, Qu H, Meng L, Liu C, Wu J, Shou C: Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol; 2010 Sep;177(3):1095-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients.
  • Tumor-associated antigens, which induce the generation of autoantibodies, are useful as cancer biomarkers in early detection and prognostic prediction of cancer.
  • To isolate a novel cancer marker, we used serum antibodies from colon cancer patients to screen a phage display peptide library.
  • A positive peptide 249C (VPLYSNTLRYGF) that could specifically react with serum from colon cancer patients was isolated, and the corresponding antigen-human arrest defective 1 (ARD1A), which shares an identical LYSNTL motif with 249C, was identified.
  • Using ELISA and immunohistochemistry, we found anti-ARD1A antibody levels in serum from patients with colon cancer were significantly higher than those in healthy volunteers (P < 0.001), and ARD1A expression was detected in 84.1% (227/270) of colon cancer tissues compared with 22.7% (55/242) of matched noncancerous tissues (P < 0.001) and 4.8% (2/42) of benign lesions (P < 0.001).
  • These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer.
  • [MeSH-major] Acetyltransferases / blood. Antigens, Neoplasm / blood. Autoantibodies / blood. Colonic Neoplasms / blood. Colonic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / isolation & purification. Blotting, Western. Cell Line, Tumor. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Epitopes / isolation & purification. Humans. Kaplan-Meier Estimate. Middle Aged. N-Terminal Acetyltransferase A. N-Terminal Acetyltransferase E. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31132-40 [15994306.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17749-57 [15755738.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1131-6 [16279846.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4350-60 [16518407.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10677-82 [17108104.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):619-26 [17998402.001]
  • [Cites] Cancer Lett. 2008 Jun 8;264(1):83-92 [18325661.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Histopathology. 2009 Feb;54(3):309-18 [19236507.001]
  • [Cites] Biochem J. 2009 Apr 1;419(1):133-9 [18973474.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):909-15 [19287988.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15209-14 [11742062.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):636-43 [12079511.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2572-82 [15352232.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):16-20 [7505195.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4656-62 [15536075.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):433-43 [15496142.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 20639454.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  • [Other-IDs] NLM/ PMC2928944
  •  go-up   go-down


37. Husillos Alonso A, Subirá Ríos D, Molina Escudero R, Hernández Fernández C: Villous adenoma in augmentation colocystoplasty asociated to infiltrating urotelial cancer in bladder remanent. Arch Esp Urol; 2010 Dec;63(10):876-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Villous adenoma is a benign neoplasm that occurs in the colonic mucosa and shows a high ability to become a malignant colonic cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187572.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


38. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutation frequency in carcinomas, benign and malignant polyps was 43, 49, and 69%, respectively.
  • In patients with colorectal carcinoma the mutation frequency in the K-ras gene was not associated with disease onset age, location, and the extent of tumor differentiation while it was associated with the stage of tumor process.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


39. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • Furthermore, MR colography evaluating the rest of the colon past the stenosis was possible with all patients.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • Furthermore, the potential is big in performing a full preoperative colon evaluation even in patients with obstructing cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


40. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


41. Choi YJ, Park SH, Lee SS, Choi EK, Yu CS, Kim HC, Kim JC: CT colonography for follow-up after surgery for colorectal cancer. AJR Am J Roentgenol; 2007 Aug;189(2):283-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The appearances of anastomotic recurrences at CTC overlap with those of more common inflammatory polyps and rare benign ulcers.
  • [MeSH-minor] Colonic Polyps / radiography. Colonoscopy. Contrast Media. Humans. Neoplasm Recurrence, Local / radiography. Postoperative Complications / radiography. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646452.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 13
  •  go-up   go-down


42. Willis S, Schumpelick V: [Open colon surgery]. Chirurg; 2005 Nov;76(11):1073-81
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Open colon surgery].
  • Open resection of the colon is one of the most frequent abdominal operations, which clearly indicates the great importance of colon carcinomas.
  • In this respect, the techniques employed are strictly standardized: right hemicolectomy for right colon carcinoma, transverse resection for right colon carcinoma, left hemicolectomy for descendent colon carcinoma, and sigmoid resection for sigmoid carcinoma.
  • In case of benign underlying disease, the operational method depends largely on the extent to which the intestine is affected and can include anything from simple colotomy and polyp removal to colectomy for toxic megacolon.
  • Elective colon surgery is usually primary, but in emergencies a protective stoma might be necessary.
  • Standardized indication and operational techniques enable low perioperative mortality and complication rates that make open colon resection usually un-problematic even in very old patients.
  • [MeSH-minor] Anastomosis, Surgical / methods. Colon / pathology. Colonic Polyps / mortality. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Surgical Staplers. Surgical Wound Dehiscence / mortality. Survival Analysis. Suture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1988 May;75(5):409-15 [3292002.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1071-8 [15316639.001]
  • (PMID = 16240155.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Sasaki Y, Niwa Y, Hirooka Y, Ohmiya N, Itoh A, Ando N, Miyahara R, Furuta S, Goto H: The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum. Endoscopy; 2005 Feb;37(2):154-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum.
  • The aim of this study was to evaluate the use of EUS-FNA for the diagnosis of lesions either within or adjacent to the wall of the colon and rectum.
  • PATIENTS AND METHODS: A total of 22 patients with a lesion within the wall of, or adjacent to, the colon or rectum underwent EUS-FNA.
  • In the four patients who had lesions located proximal to the sigmoid colon, EUS-FNA was performed using a guide wire and overtube.
  • The success rates for adequate tissue sampling and for detecting malignant and benign masses by EUS-FNA were evaluated and the success rate for detection was compared with the success rate of EUS and computed tomography.
  • The overall rate of detection of malignant and benign masses was 95.5 % (21/22) for EUS-FNA and 81.8 % (18/22) for pre-EUS-FNA imaging investigations.
  • Of the 11 patients in the previous +ve group, ten were diagnosed with recurrences of primary malignancies; of the 11 patients in the previous -ve group, four were diagnosed with primary malignancies and seven were diagnosed with benign lesions.
  • CONCLUSIONS: EUS-FNA is a safe technique which is useful in the planning of treatment for patients who have a mass within the wall or adjacent to the wall of the entire length of the colon or rectum.
  • [MeSH-major] Biopsy, Fine-Needle. Colonic Neoplasms / pathology. Endosonography. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692931.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg; 2005 Jan;79(1):263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was benign, repeat clinical imaging, or long-term follow-up.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fluorodeoxyglucose F18. Granuloma / diagnosis. Histiocytosis / complications. Histiocytosis / diagnosis. Histoplasmosis / complications. Histoplasmosis / diagnosis. Humans. Kidney Neoplasms / pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis / diagnosis. Silicosis / complications. Silicosis / diagnosis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620955.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


45. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Rettenmaier M, Epstein HD, Abaid LN, Bechtol KA, Goldstein BH: Leiomyosarcoma with synchronous clear cell ovarian carcinoma. Onkologie; 2010;33(12):695-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine leiomyomas are typically considered benign lesions.
  • Following surgery, the patient was diagnosed with a 16 cm ovarian mass and a synchronous leiomyosarcoma; the latter neoplasm appeared to originate from a previously resected uterine leiomyoma.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cell Transformation, Neoplastic / pathology. Chemotherapy, Adjuvant. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Female. Humans. Hysterectomy. Intestinal Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestinal Neoplasms / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Omentum / pathology. Omentum / surgery. Ovariectomy. Salpingectomy. Uterus / pathology


47. Winter H, Lang RA, Spelsberg FW, Jauch KW, Hüttl TP: Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis; 2007 Nov;22(11):1377-81
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon.
  • BACKGROUND AND AIMS: Endoscopic treatment of large or colonoscopically inaccessible polyps or early stage tumors in the colon holds the risk of incomplete resection and colonic perforation.
  • Aim of this study was to assess the feasibility and outcome of patients operated on by laparoendoscopic rendezvous procedures at the colon.
  • MATERIALS AND METHODS: The medical records of 38 patients (21 male, 17 female, median age 66 years [range 39-90]) undergoing rendezvous surgery at the colon were reviewed prospectively.
  • A benign lesion was confirmed histologically in 31 patients.
  • In five cases, histopathologic diagnosis revealed a malignancy necessitating colonic surgery.
  • CONCLUSION: Rendezvous procedures offer a safe, minimal-invasive therapeutic approach allowing the resection of benign sessile or colonoscopically inaccessible localized polyps and of early stage colon cancer.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Colonic Polyps / therapy. Colonoscopy / methods. Laparoscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646999.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Sajid MS, Rimpel J, Iftikhar M, Baig MK: Use of health related quality of life tools in colorectal surgery. Acta Chir Belg; 2007 Nov-Dec;107(6):623-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal Quality of Life Index (GIQLI) for benign anorectal conditions, European Organization for the Research and Treatment of Cancer (EORTC QLQ-C30), EORTC QLQ-CR38 and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) for colorectal cancer and Inflammatory Bowel Disease Questionnaire (IBDQ) for all types of inflammatory bowel disease are being used frequently to assess the quality of life after surgery.
  • [MeSH-major] Colonic Diseases / surgery. Health Status. Quality of Life. Rectal Diseases / surgery
  • [MeSH-minor] Colonic Neoplasms / surgery. Colonic Pouches. Digestive System Surgical Procedures. Humans. Inflammatory Bowel Diseases / surgery. Laparoscopy. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274174.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


49. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Reoperation


50. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res; 2006 Sep 1;12(17):5158-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
  • PURPOSE: Human Cripto-1 (CR-1), a cell membrane glycosylphosphatidylinositol-anchored glycoprotein that can also be cleaved from the membrane, is expressed at high levels in several different types of human tumors.
  • We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.
  • EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.
  • A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).
  • Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).
  • Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.
  • CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951234.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


51. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.
  • In addition, Pyrosequencing proved superior to dideoxy sequencing in the detection of KRAS mutations from DNA mixtures of paraffin-embedded colon cancer and normal tissue as well as from paraffin-embedded pancreatic cancers.
  • It is particularly useful for tumors containing abundant non-neoplastic cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


52. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


57. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol; 2010 Mar;73(3):185-91
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pdcd4, a colon cancer prognostic that is regulated by a microRNA.
  • The novel tumor suppressor Pdcd4 inhibits neoplastic transformation, tumor progression and translation.
  • Furthermore, we will review the first translational and clinical results concerning the prognostic value of Pdcd4, in particular our own data that show Pdcd4 to be a novel and independent prognostic factor in colorectal cancer, and a potential supportive diagnostic tool for discriminating normal colonic tissues from benign adenomas and colorectal carcinomas.
  • [MeSH-minor] Animals. Humans. Neoplasm Invasiveness / genetics. Neoplasm Metastasis / genetics. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19836969.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / MicroRNAs; 0 / PDCD4 protein, human; 0 / RNA-Binding Proteins
  • [Number-of-references] 78
  •  go-up   go-down


58. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA: Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer; 2009 Jun;45(9):1654-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD74 mRNA (p31 and p41 splice variants) and immunoreactive CD74 protein levels were significantly lower in small intestinal and colonic Apc(Min/+) mouse adenomas compared with histologically normal mucosa.
  • Down-regulation of CD74 during Apc(Min/+) mouse intestinal tumorigenesis does not model increased CD74 expression at the early, benign stages of human colorectal carcinogenesis.
  • [MeSH-major] Adenoma / immunology. Antigens, Differentiation, B-Lymphocyte / metabolism. Antigens, Neoplasm / metabolism. Colorectal Neoplasms / immunology. Histocompatibility Antigens Class II / metabolism
  • [MeSH-minor] Animals. Down-Regulation / immunology. Gene Expression Regulation, Neoplastic / immunology. Humans. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Mice. Mice, Inbred C57BL. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269807.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G116/146; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class II; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / invariant chain; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


59. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Fenech DS, Takahashi T, Liu M, Spencer L, Swallow CJ, Cohen Z, Macrae HM, McLeod RS: Function and quality of life after transanal excision of rectal polyps and cancers. Dis Colon Rectum; 2007 May;50(5):598-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients having a transanal excision at the Mount Sinai Hospital from 1989 to 2002 were included if the indication for surgery was a benign or malignant neoplasm.
  • [MeSH-major] Colonic Polyps / surgery. Fecal Incontinence / physiopathology. Quality of Life. Recovery of Function. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309002.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


62. Vogelsang H, Siewert JR: Endocrine tumours of the hindgut. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):739-51
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer.
  • Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy.
  • As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Anastomosis, Surgical. Biopsy, Needle. Colonoscopy / methods. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Rare Diseases. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253898.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


63. Matsumoto T, Hirano S, Yada K, Shibata K, Sasaki A, Kamimura T, Ohta M, Kitano S, Kashima K: Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. J Clin Gastroenterol; 2005 Mar;39(3):253-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature.
  • BACKGROUND: In general, serous cystic neoplasms of the pancreas are thought to be benign.
  • Malignant serous cystic neoplasm of the pancreas is a rare clinical entity.
  • CASE REPORT: We report the case of an 87-year-old woman with a serous microcystic neoplasm in the tail of the pancreas that behaved in a malignant fashion.
  • The neoplasm had also invaded the colonic mesentery and splenic hilum.
  • The pancreatic lesion was diagnosed as a large malignant serous cystic neoplasm, and the patient underwent distal pancreatectomy with splenectomy and segmental colectomy.
  • The resected specimen contained a large tumor, 12 x 9 x 8 cm, which occupied the body and tail of the pancreas.
  • Histologically, the tumor was indistinguishable from serous cystadenoma.
  • However, the tumor had invaded surrounding tissues including the splenic vein, and there were splenic invasion and a regional lymph node metastasis.
  • DISCUSSION: There are few reported cases of malignant serous cystic neoplasm, in which malignancy was histologically confirmed in the resected specimen.
  • There are no reports of a negative outcome with complete resection of the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718870.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


64. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


65. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH: Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res; 2007 Jun 15;67(12):5600-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
  • Colon cancer-specific antigen (CCSA)-3 and CCSA-4 are novel colon cancer markers identified by focused proteomic analysis of nuclear structural proteins.
  • Serum samples from 107 subjects undergoing colonoscopy, 28 subjects with colorectal cancer, and 125 subjects with benign disease or other types of cancer were evaluated.
  • Individuals who underwent colonoscopy were classified into mutually exclusive categories, including normal colon, hyperplastic polyp, nonadvanced adenoma, and advanced adenoma.
  • [MeSH-major] Adenocarcinoma / blood. Adenoma / blood. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH. Cancer Res. 2013 Jan 15;73(2):1034 [23271721.001]
  • (PMID = 17575123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / colon-specific antigen
  •  go-up   go-down


66. Rosin D, Zmora O, Hoffman A, Khaikin M, Munz Y, Zakai BB, Goldes Y, Shabtai EL, Shabtai M, Ayalon A: [Laparoscopic colon and rectal surgery--after ten years and 350 operations]. Harefuah; 2007 Mar;146(3):176-80, 247-8
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic colon and rectal surgery--after ten years and 350 operations].
  • Laparoscopic colon and rectal surgery has not yet been adopted by the majority of surgeons, due to technical complexity and reservation regarding its oncological safety.
  • We present our experience with laparoscopic surgery of the large bowel over the last ten years.
  • AIM: To assess the short and intermediate term results after laparoscopic colon and rectal surgery, and to summarize the long term results after curative colectomy for malignancy.
  • METHODS: Data regarding all patients undergoing laparoscopic colon and rectal surgery was prospectively entered into a computerized database, including demographics, surgical technique and perioperative course.
  • RESULTS: Over a period of ten years, 350 various laparoscopic colon and rectal procedures were performed, for both benign and malignant conditions.
  • CONCLUSIONS: The laparoscopic approach to large bowel surgery enables short and long term results comparable with those achieved by open technique, regarding perioperative complication rate and long term oncologic outcome.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infection / epidemiology. Infection / mortality. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460920.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


67. Leinung S, Möbius C, Udelnow A, Hauss J, Würl P: Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. Eur J Surg Oncol; 2007 May;33(4):508-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience.
  • RESULTS: We treated 597 patients with soft tissue tumors.
  • Open biopsy revealed soft tissue sarcoma in 318 cases, benign mesenchymal tumor in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
  • The primary carcinomas were lung cancer in 26 patients, breast cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
  • CONCLUSIONS: In our collective with soft tissue tumor, 50% of the patients had the diagnosis of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a benign tumor.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081724.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Herawi M, Leppert JT, Thomas GV, De Kernion JB, Epstein JI: Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: support for "seed and soil" hypothesis of bladder recurrence. Urology; 2006 Apr;67(4):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To explore the underlying mechanism of tumor regrowth in cases of noninvasive urothelial carcinoma that recur in unusual anatomic locations.
  • One had presented as an implant in the peritoneal investment of the bladder dome and the other as multiple implants growing on the benign surface of the colonic mucosa of an orthotopic neobladder distant from the anastomosis site.
  • Although the urinary bladder was free of neoplastic changes at nephroureterectomy, both patients also developed several papillary tumors within the bladder shortly after the removal of the kidney.
  • CONCLUSIONS: After clinicopathologic correlation, the mode of tumor spread in these cases was best explained by the "seeding/implantation" theory.
  • The urothelial tumor cells in each of these cases demonstrated the ability to implant themselves not only in the urothelium of the bladder but also in the colonic mucosa of a constructed neobladder and on the peritoneal surface.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Neoplasm Recurrence, Local / etiology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged, 80 and over. Colon / surgery. Female. Humans. Ileum / surgery. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566991.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


70. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • METHODS: The expression of XAF1 in four human colon cancer cell lines (Colo205, Colo320, SW1116, LoVo) and in samples from 70 patients with CRC was analyzed by reverse transcriptase-polymerase chain reaction.
  • RESULTS: A low concentration of XAF1 mRNA was detectable in the three colon cancer cell lines other than Colo205, which showed the strongest expression of XAF1.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


71. Hemandas AK, Robson NK, Hickish T, Talbot RW: Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis; 2008 May;10(4):386-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this retrospective study was to assess the significance of incidental focal colonic lesions on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) scans in patients undergoing staging for noncolorectal cancer.
  • METHOD: Of the 110 patients in our PET/CT database, 10 were found to have abnormally high uptake of tracer in their large bowel.
  • CONCLUSION: Benign colonic polyps produce high-intensity focal FDG uptake in large bowel.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Gastrointestinal Neoplasms / pathology. Head and Neck Neoplasms / pathology. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608754.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA: Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol; 2008 Feb;34(2):196-201
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare disease with an estimated incidence of 1 per million per year, and is thought to originate usually from an appendiceal mucinous epithelial neoplasm.
  • Coincidentally, an additional epithelial colonic neoplasm was found in 13% of patients with an appendiceal epithelial lesion.
  • A mucinous epithelial neoplasm was identified in 0.3% (73% benign, 27% malignant) of appendiceal specimens and 20% of these patients developed PMP.
  • For mucocele and non-mucinous neoplasm the association with PMP was only 2% and 3%, respectively.
  • Furthermore there is a considerable risk of an additional colonic epithelial neoplasm in patients with an epithelial neoplasm at appendectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524597.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Ruiz-Tovar J, Reguero-Callejas ME, González Palacios F: Inflammation and perforation of a solitary diverticulum of the cecum. A report of 5 cases and literature review. Rev Esp Enferm Dig; 2006 Nov;98(11):875-80
MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary diverticulum of the cecum is a benign condition uncommon in the Western world, and with a higher incidence in Asian population.
  • In spite of the information provided by ultrasonography or CT scans, a correct preoperative diagnosis is still difficult to reach, and is usually arrived at in the operating theater; differentiation from a neoplasm may be also sometimes complicated, and a wide surgical resection is usually required for such cases.
  • [MeSH-major] Diverticulitis, Colonic / complications. Diverticulum, Colon / complications. Intestinal Perforation / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198478.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


74. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down






Advertisement